AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. LFVN
  4. [Form 4] Lifevantage Corporation Insider Trading Activity

[Form 4] Lifevantage Corporation Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Kristen Cunningham, Chief Sales Officer of LifeVantage Corp (LFVN), reported changes in her beneficial ownership on a Form 4 covering transactions dated 08/31/2025. The filing shows conversion/acquisition of 17,752 and 26,150 performance restricted stock units (PRSUs) into common stock at no cash price, an ESPP purchase of 254 shares, and a sale of 21,801 common shares at $13.10 per share. After the transactions, reported beneficial ownership totals shown range between 134,357 and 160,507 shares depending on which line is referenced; derivative holdings converted on a one-for-one basis into common stock.

Kristen Cunningham, Chief Sales Officer di LifeVantage Corp (LFVN), ha segnalato variazioni nella sua titolarit脿 effettiva tramite un Modulo 4 relativo a operazioni datate 31/08/2025. La comunicazione indica la conversione/acquisizione di 17.752 e 26.150 performance restricted stock unit (PRSUs) in azioni ordinarie a titolo gratuito, un acquisto ESPP di 254 azioni e la vendita di 21.801 azioni ordinarie al prezzo di $13,10 per azione. Dopo le operazioni, la partecipazione beneficiaria riportata risulta compresa tra 134.357 e 160.507 azioni a seconda della riga di riferimento; i titoli derivati sono stati convertiti in azioni ordinarie con rapporto uno a uno.

Kristen Cunningham, Chief Sales Officer de LifeVantage Corp (LFVN), inform贸 cambios en su propiedad beneficiaria mediante un Formulario 4 relativo a transacciones con fecha 31/08/2025. El documento refleja la conversi贸n/adquisici贸n de 17.752 y 26.150 unidades restringidas por desempe帽o (PRSUs) en acciones ordinarias sin coste, una compra ESPP de 254 acciones y la venta de 21.801 acciones ordinarias a $13,10 por acci贸n. Tras las operaciones, la participaci贸n beneficiaria notificada oscila entre 134.357 y 160.507 acciones seg煤n la l铆nea consultada; las posiciones derivadas se convirtieron en acciones ordinarias en una proporci贸n uno a uno.

Kristen Cunningham, LifeVantage Corp (LFVN)鞚� Chief Sales Officer電� 2025-08-31鞛� 瓯半灅毳� 韽暔頃� 靻岇湢 甏�霠� 氤�霃欖潉 Form 4搿� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滌棎電� 17,752 氚� 26,150 靹标臣 鞝滍暅欤检嫕雼渼(PRSUs)臧� 氍挫儊鞙茧 氤错喌欤茧 鞝勴櫂/旆摑霅� 瓴�, ESPP毳� 韱淀暅 254欤� 毵れ垬, 攴鸽Μ瓿� 氤错喌欤� 21,801欤茧ゼ 欤茧嫻 $13.10鞐� 毵る弰頃� 靷嫟鞚� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 瓯半灅 頉� 氤搓碃霅� 鞁れ 靻岇湢電� 彀胳“頃� 頃鞐� 霐半澕 134,357欤检棎靹� 160,507欤� 靷澊鞚措┌, 韺岇儩 氤挫湢電� 1雽�1 牍勳湪搿� 氤错喌欤茧 鞝勴櫂霅橃棃鞀惦媹雼�.

Kristen Cunningham, Chief Sales Officer de LifeVantage Corp (LFVN), a d茅clar茅 des changements dans sa d茅tention b茅n茅ficiaire via un Formulaire 4 couvrant des op茅rations dat茅es du 31/08/2025. Le d茅p么t indique la conversion/acquisition de 17鈥�752 et 26鈥�150 unit茅s d'actions restreintes li茅es 脿 la performance (PRSUs) en actions ordinaires sans contrepartie financi猫re, un achat ESPP de 254 actions et la vente de 21鈥�801 actions ordinaires au prix de $13,10 par action. Apr猫s ces op茅rations, la d茅tention b茅n茅ficiaire d茅clar茅e varie entre 134鈥�357 et 160鈥�507 actions selon la ligne consult茅e; les instruments d茅riv茅s ont 茅t茅 convertis en actions ordinaires 脿 raison d'une pour une.

Kristen Cunningham, Chief Sales Officer von LifeVantage Corp (LFVN), meldete 脛nderungen ihres wirtschaftlichen Eigentums in einem Form 4 f眉r Transaktionen datiert 31.08.2025. Die Einreichung zeigt die Umwandlung/Erwerb von 17.752 und 26.150 performance-restricted Stock Units (PRSUs) in Stammaktien ohne Barzahlung, einen ESPP-Kauf von 254 Aktien sowie den Verkauf von 21.801 Stammaktien zu $13,10 je Aktie. Nach den Transaktionen liegt das gemeldete wirtschaftliche Eigentum je nach gew盲hlter Zeile zwischen 134.357 und 160.507 Aktien; derivative Best盲nde wurden eins zu eins in Stammaktien umgewandelt.

Positive
  • Converted PRSUs to common stock totaling 17,752 and 26,150 units, increasing equity alignment with shareholders
  • Participated in ESPP with a purchase of 254 shares, indicating continued employee ownership
  • Disclosures reference grant dates and one-for-one conversion, improving transparency
Negative
  • Sold 21,801 shares at $13.10, representing insider liquidity that partially reduces holdings
  • Beneficial ownership figures vary by line (134,357 to 160,507), which may require careful reconciliation by investors

Insights

TL;DR: Insider activity shows mixed transactions: PRSU conversions and an ESPP buy alongside a notable open-market sale.

The filing documents non-cash PRSU conversions totaling 43,902 units (17,752 + 26,150) that convert one-for-one into common shares, increasing share exposure without cash outlay. The ESPP purchase of 254 shares is routine employee participation. The sale of 21,801 shares at $13.10 partially offsets those increases and represents realized insider liquidity. Overall, the activity is typical compensation-related vesting plus a voluntary sale and does not by itself indicate a material change to company fundamentals.

TL;DR: Transactions appear consistent with executive compensation vesting and routine insider selling; disclosures are timely and complete.

The report identifies PRSU grants from prior years (grants dated Aug 24, 2023 and Aug 26, 2024) that vested or converted on 08/31/2025 and are disclosed as required. The presence of an ESPP purchase and a contemporaneous open-market sale suggests portfolio rebalancing or personal liquidity rather than governance concerns. The Form 4 is signed via power of attorney and includes explanatory footnotes about grant dates and one-for-one conversion, aligning with standard disclosure practice.

Kristen Cunningham, Chief Sales Officer di LifeVantage Corp (LFVN), ha segnalato variazioni nella sua titolarit脿 effettiva tramite un Modulo 4 relativo a operazioni datate 31/08/2025. La comunicazione indica la conversione/acquisizione di 17.752 e 26.150 performance restricted stock unit (PRSUs) in azioni ordinarie a titolo gratuito, un acquisto ESPP di 254 azioni e la vendita di 21.801 azioni ordinarie al prezzo di $13,10 per azione. Dopo le operazioni, la partecipazione beneficiaria riportata risulta compresa tra 134.357 e 160.507 azioni a seconda della riga di riferimento; i titoli derivati sono stati convertiti in azioni ordinarie con rapporto uno a uno.

Kristen Cunningham, Chief Sales Officer de LifeVantage Corp (LFVN), inform贸 cambios en su propiedad beneficiaria mediante un Formulario 4 relativo a transacciones con fecha 31/08/2025. El documento refleja la conversi贸n/adquisici贸n de 17.752 y 26.150 unidades restringidas por desempe帽o (PRSUs) en acciones ordinarias sin coste, una compra ESPP de 254 acciones y la venta de 21.801 acciones ordinarias a $13,10 por acci贸n. Tras las operaciones, la participaci贸n beneficiaria notificada oscila entre 134.357 y 160.507 acciones seg煤n la l铆nea consultada; las posiciones derivadas se convirtieron en acciones ordinarias en una proporci贸n uno a uno.

Kristen Cunningham, LifeVantage Corp (LFVN)鞚� Chief Sales Officer電� 2025-08-31鞛� 瓯半灅毳� 韽暔頃� 靻岇湢 甏�霠� 氤�霃欖潉 Form 4搿� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滌棎電� 17,752 氚� 26,150 靹标臣 鞝滍暅欤检嫕雼渼(PRSUs)臧� 氍挫儊鞙茧 氤错喌欤茧 鞝勴櫂/旆摑霅� 瓴�, ESPP毳� 韱淀暅 254欤� 毵れ垬, 攴鸽Μ瓿� 氤错喌欤� 21,801欤茧ゼ 欤茧嫻 $13.10鞐� 毵る弰頃� 靷嫟鞚� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 瓯半灅 頉� 氤搓碃霅� 鞁れ 靻岇湢電� 彀胳“頃� 頃鞐� 霐半澕 134,357欤检棎靹� 160,507欤� 靷澊鞚措┌, 韺岇儩 氤挫湢電� 1雽�1 牍勳湪搿� 氤错喌欤茧 鞝勴櫂霅橃棃鞀惦媹雼�.

Kristen Cunningham, Chief Sales Officer de LifeVantage Corp (LFVN), a d茅clar茅 des changements dans sa d茅tention b茅n茅ficiaire via un Formulaire 4 couvrant des op茅rations dat茅es du 31/08/2025. Le d茅p么t indique la conversion/acquisition de 17鈥�752 et 26鈥�150 unit茅s d'actions restreintes li茅es 脿 la performance (PRSUs) en actions ordinaires sans contrepartie financi猫re, un achat ESPP de 254 actions et la vente de 21鈥�801 actions ordinaires au prix de $13,10 par action. Apr猫s ces op茅rations, la d茅tention b茅n茅ficiaire d茅clar茅e varie entre 134鈥�357 et 160鈥�507 actions selon la ligne consult茅e; les instruments d茅riv茅s ont 茅t茅 convertis en actions ordinaires 脿 raison d'une pour une.

Kristen Cunningham, Chief Sales Officer von LifeVantage Corp (LFVN), meldete 脛nderungen ihres wirtschaftlichen Eigentums in einem Form 4 f眉r Transaktionen datiert 31.08.2025. Die Einreichung zeigt die Umwandlung/Erwerb von 17.752 und 26.150 performance-restricted Stock Units (PRSUs) in Stammaktien ohne Barzahlung, einen ESPP-Kauf von 254 Aktien sowie den Verkauf von 21.801 Stammaktien zu $13,10 je Aktie. Nach den Transaktionen liegt das gemeldete wirtschaftliche Eigentum je nach gew盲hlter Zeile zwischen 134.357 und 160.507 Aktien; derivative Best盲nde wurden eins zu eins in Stammaktien umgewandelt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cunningham Kristen
(Last) (First) (Middle)
3300 TRIUMPH BLVD, SUITE 700
(Street)
LEHI UT 84043
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Lifevantage Corp [ LFVN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Sales Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/31/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/31/2025 M 17,752(1) A $0 134,357(2) D
Common Stock 08/31/2025 M 26,150(3) A $0 160,507 D
Common Stock 08/31/2025 F 21,801 D $13.1 138,706 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Performance Restricted Stock Units (4) 08/31/2025 M 17,752 (1) (1) Common Stock 17,752 $0 5,917 D
Performance Restricted Stock Units (4) 08/31/2025 M 26,150 (3) (3) Common Stock 26,150 $0 13,075 D
Explanation of Responses:
1. On August 24, 2023, the reporting person was granted Performance Restricted Stock Units ("PRSUs") which vest upon achievement of previously established time-based and financial performance criteria.
2. Includes 254 total shares purchased on August 31, 2025 under the Employee Stock Purchase Plan.
3. On August 26, 2024, the reporting person was granted PRSUs which vest upon achievement of previously established time-based and financial performance criteria.
4. PRSUs convert into common stock on a one-for-one basis.
Remarks:
/s/ Alissa Neufeld, Power of Attorney for Kristen Cunningham 09/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What transactions did Kristen Cunningham report on Form 4 for LFVN?

The filing reports conversion/acquisition of 17,752 and 26,150 PRSUs into common stock, an ESPP purchase of 254 shares, and a sale of 21,801 shares at $13.10 per share, all dated 08/31/2025.

How do PRSUs reported by Kristen Cunningham convert into LFVN common stock?

The filing states PRSUs convert one-for-one into common stock upon vesting, as noted in the explanatory remarks.

Did the Form 4 indicate when the PRSUs were originally granted?

Yes. The filing notes PRSU grants on 08/24/2023 and 08/26/2024 tied to time-based and financial performance criteria.

What is the effect on Kristen Cunningham鈥檚 ownership after the reported transactions?

Post-transaction beneficial ownership amounts reported on the form include figures such as 134,357, 138,706, and 160,507 shares depending on the line item; the form should be consulted for precise reconciliation.

Who signed the Form 4 filing for Kristen Cunningham?

The Form 4 was signed by Alissa Neufeld, Power of Attorney for Kristen Cunningham on 09/03/2025.
Stock LFVN logo
Lifevantage Corp

NASDAQ:LFVN

LFVN Rankings

#4357 Ranked by Market Cap
#1858 Ranked by Dividends

LFVN Latest News

Sep 3, 2025
LifeVantage Announces Acquisition of LoveBiome, Expanding Leadership in Direct Sales, Microbiome Health and Wellness
Sep 2, 2025
LifeVantage to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Aug 28, 2025
LifeVantage Declares Quarterly Dividend
Aug 21, 2025
LifeVantage to Announce Fourth Quarter and Full Fiscal Year 2025 Results on September 4, 2025
Jul 24, 2025
LifeVantage To Open Iceland Market

LFVN Latest SEC Filings

Sep 3, 2025
[Form 4] Lifevantage Corporation Insider Trading Activity
Sep 3, 2025
[Form 4] Lifevantage Corporation Insider Trading Activity
Sep 3, 2025
[Form 4] Lifevantage Corporation Insider Trading Activity
Sep 3, 2025
[Form 4] Lifevantage Corporation Insider Trading Activity
Aug 28, 2025
[Form 4] Lifevantage Corporation Insider Trading Activity

LFVN Stock Data

164.91M
10.43M
15.23%
65.86%
18.78%
Packaged Foods
Pharmaceutical Preparations
United States
LEHI